There is an oddity at the centre of gout care. The cause of the disease is known, a cheap oral drug removes that cause, and a blood test shows whether it has done so. Yet in an article whose title has become a standing reproach, Doherty et al. (2012) asked why this curable disease is so seldom cured. National data from the United Kingdom gave the question numbers: the prevalence of gout was rising, only a minority of patients were prescribed urate-lowering therapy, and that proportion had not improved over many years (Kuo et al., 2015).

Most people with gout never see a rheumatologist. They are diagnosed and treated by a general practitioner, often during a flare, in an appointment of a few minutes. Any account of why urate goals are missed must therefore be an account of primary care. This article offers one. Its claim is that the shortfall is produced mainly by the way care is organised and by how the disease is understood, and only secondarily by the choices of individual patients or doctors.

The rationale is physicochemical. Monosodium urate becomes less soluble as temperature falls, and at body temperature its saturation point lies a little under 7 mg/dL (Loeb, 1972). Above that concentration crystals can form in and around joints; below it, existing deposits slowly dissolve. Flares, tophi and joint damage all follow from the crystal burden (Dalbeth et al., 2021). A treatment strategy that lowers urate far enough for long enough should therefore abolish the disease, and the lower the level, the faster the deposits clear.

Rheumatology guidance is built on that reasoning. Table 1 sets out the positions of the main guideline bodies. The American College of Rheumatology strongly recommends a treat-to-target strategy with dose titration guided by serial urate measurement (FitzGerald et al., 2020). EULAR sets the same threshold, with a lower one for severe disease until crystals have cleared (Richette et al., 2017), and the British guideline asks for the lower level from the outset (Hui et al., 2017).

If the principle is this clear, the failure must lie in its execution. Four features of everyday practice, taken together, account for most of it.

The view taken here is open to three objections, and each deserves a fair hearing.

The first is that the target itself is unproven. The American College of Physicians concluded that evidence was insufficient to say whether treating to a urate target improves outcomes compared with adjusting treatment according to symptoms (Qaseem et al., 2017). The point is methodologically correct in a narrow sense: at the time, no trial had randomised patients to the two strategies with flares as the outcome. Rheumatology bodies replied that the biology, the consistent relation between achieved urate and clinical outcomes, and the weight of indirect evidence justified the target (Dalbeth et al., 2017). For a general practitioner the result was two authoritative documents pointing in different directions, and the one requiring less work was always likely to prevail.

The second objection is that patients do not want lifelong tablets and will not take them. The evidence does not support this as a fixed fact. In a proof-of-concept study, patients who were given a full explanation of gout and involved in decisions accepted treatment and nearly all reached the target (Rees et al., 2013). Reluctance appears to depend heavily on what patients have been told.

The third is safety. Allopurinol hypersensitivity is rare but can be fatal, and the cardiovascular safety of the alternative xanthine oxidase inhibitor, febuxostat, has been debated. These concerns call for care in choosing and starting a drug, and they are the reason for a low starting dose and gradual escalation. They are not a reason to leave a patient on a dose that exposes them to the risks of treatment without its benefit.

The strongest evidence that the problem is one of organisation comes from trials that changed the organisation and nothing else. In a randomised trial in the United Kingdom, care led by research nurses who educated patients, involved them in decisions and titrated therapy to target brought the large majority of patients to the urate goal at two years, against a minority under usual general practitioner care, with fewer flares, less tophaceous disease and favourable cost-effectiveness (Doherty et al., 2018). A site-randomised trial in the United States reported better adherence and target attainment with a pharmacist-led programme than with usual care (Mikuls et al., 2019). The drugs were the same in both arms of each trial. What differed was that a named person explained the disease, checked the urate and adjusted the dose. Figure 1 shows the loop that these models put into practice.

Three implications follow for primary care. Responsibility for titration should be assigned, and it need not be to a doctor; practice nurses and pharmacists already manage hypertension and anticoagulation by protocol. Serum urate should be treated as a monitored quantity, with a register of patients on urate-lowering therapy and a recall when no recent value is on file. And the first conversation about gout should be moved out of the flare consultation into a planned visit at which the cause of the disease, the purpose of the tablets and the likelihood of early flares can be explained properly.

None of this demands new science. It does demand that health systems regard gout as they regard other long-term conditions with a measurable target. Whether models proven in trials can be sustained in routine practice, with ordinary staffing and competing demands, is still to be demonstrated, and evaluations of implementation at scale would be more useful now than further comparisons of drugs.

Urate goals are rarely reached in primary care because the conditions for reaching them are absent: the disease is framed as episodic, the dose is fixed at its starting level, early flares go unexplained, the number is nobody's task, and guideline disagreement has excused all of this. Where those conditions have been supplied, by nurses or pharmacists working to a simple protocol, most patients have reached the target and their gout has receded. The remedy lies less in persuading individual clinicians than in giving serum urate the same standing in practice systems as blood pressure.

To be declared by the author(s) before publication.

To be declared by the author(s) before publication.